Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina.

ABSTRACT:

Introduction

Pulmonary arterial hypertension is a progressive haemodynamic disease with high morbidity and mortality. Of the different treatments available, the prostacyclin analogues are the drugs of choice for high-risk patients, with treprostinil being the most commonly used drug in Argentina.

Methodology

The objective of this study is to perform a retrospective evaluation of the efficacy and safety of subcutaneous treprostinil in regular clinical practice in Argentina in 51 patients with pulmonary arterial hypertension after 12 months of follow-up.

Results

The results showed that treatment with subcutaneous treprostinil is associated with a significant improvement in different clinical efficacy parameters: 65% reduction in advanced functional class (p < 0.0

SUBMITTER: Lescano A 

PROVIDER: S-EPMC9629562 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature